AIDSWEEKLY Plus; Monday, January 26, 2009
Staff Medical Writers

NewsRx -- Researchers have discovered a potentially important new resistance factor in the battle against HIV: blood types. An international team of researchers from Canadian Blood Services, The Hospital for Sick Children (SickKids) and Lund University in Sweden have discovered that certain blood types are more predisposed to contracting HIV, while others are more effective at fending it off (see also Canadian Blood Services).

A carbohydrate-containing antigen, termed Pk blood group which is distinct from the well-known ABO and Rh blood grouping systems, is present at variable levels on the surface of white and red blood cells in the general population. A study published in Blood, which is currently available online, shows that cells from rare individuals ( 1 in a million) who produce excess of this blood group antigen have dramatically reduced sensitivity to HIV infection. Conversely, another slightly more common subgroup of people who do not produce any Pk ( 5 in a million) was found to be much more susceptible to the virus.

"This study is not suggesting that your blood type alone determines if you will get HIV," says lead author Dr. Don Branch of Canadian Blood Services. "However, it does suggest that individuals who are exposed to the virus, may be helped or hindered by their blood status in fighting the infection."

Increasing the level of the Pk antigen in cells in the laboratory also resulted in heightened resistance to HIV, while lowering it increased susceptibility. The Pk molecule has been previously studied extensively by The Research Institute at the Hospital for Sick Children Senior Scientist Dr. Cliff Lingwood; Lund University's Dr. Martin Olsson has identified underlying genetic reasons for Pk blood group variation.

"This discovery implicates the Pk level as a new risk factor for HIV infection and demonstrates the importance of blood-group-related science," says Dr. Olsson. "The conclusions of this study pave the way for novel therapeutic approaches to induce HIV resistance and promote further understanding of the pandemic as a whole," says Dr. Lingwood.

Keywords: HIV/AIDS, AIDS, Acquired Immunodeficiency Syndrome, HIV, Human Immunodeficiency Virus, Virology, Canadian Blood Services.

This article was prepared by AIDS Weekly editors from staff and other reports.

2009-01-26
AW090110

Copyright © 2009 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the Elton John AIDS Foundation UK, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.